CD4 and neoplasm: Our results demonstrate that the combined treatment with low-dose HMGN1 and anti-CD4 depleting antibody exerts synergistic anti-tumor effects by promoting CD8+ T cell activation, expansion, and by counteracting exhaustion of activated CD8+ T cells in the tumor.